Impact of National Health Insurance on the survival rate of patients with osteosarcoma in Taiwan: Review of 74 patients

Kaohsiung Journal of Medical Sciences

Volumn 20, Issue 5, 2004, Pages 230-234

  Poon, Kein Boon ^a   Chien, Song Hsiung ^a   Lin, Gau Tyan ^a   Wang, Gwo Jaw ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

National Health Insurance; Osteosarcoma; Survival rate; Taiwan

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HISTOLOGY; HUMAN; LIMB SALVAGE; MALE; MEDICAL CARE; MEDICAL FEE; NATIONAL HEALTH INSURANCE; OSTEOSARCOMA; OUTCOMES RESEARCH; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGNOSIS; REVIEW; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TAIWAN;

EID: 3042720536     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70111-1     Document Type: Review

References (15)

1. Papagelopoulos PJ, Galanis EC, Vlastou C, et al. Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics 2000;23:858-67.
2. Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997;8:899-903.
3. Provisor J, Ettinger LJ, Nachman JB, et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the children's cancer group. J Clin Oncol 1997;15:76-84.
4. Sluga M, Windhager R, Lang S, et al. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop 1999;358:120-7.
5. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153:106-20.
6. Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb: amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002;84:88-92.
7. Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 2002;84:395-400.
8. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-21.
9. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer 1992;69:698-708.
10. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-7.
11. Pochanugool L, Subhadharaphandou T, Dhanachai M, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop 1997;345:206-14.
12. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998;69:230-6.
13. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in Taiwan: results from a natural experiment. JAMA 1997;278:89-93.
14. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27.
15. Rougraff BT, Simon MA, Kneisl JS, et al. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 1994;76:649-56.